HGS To Focus On "Core Pipeline" As Part Of Cost Reduction Plan; CEO Steps Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Human Genome Sciences plans to reduce its headcount by 20% and limit the number of drugs in early development. In 2004 and 2005, the company will focus on five products in immunology/infectious disease and oncology.
You may also be interested in...
Human Genome Sciences CEO Is Former TAP President Thomas Watkins
Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.
Human Genome Sciences CEO Is Former TAP President Thomas Watkins
Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.
GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon
The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.